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ABSTRACT 
Objectives Continuous positive airway pressure (CPAP) improves upper airway obstruction 
in patients with obstructive sleep apnoea (OSA), who often are overweight-obese. Although it 
is thought that CPAP improves long-term blood pressure control (BP), the impact of acute 
and short-term CPAP use on the cardiovascular system in obese patients has not been 
described in detail.  
Methods Obese patients (body mass index, BMI>25kg/m2) with OSA were studied awake, 
supine during incremental CPAP titration (4-20cmH2O, +2cmH2O/3mins). BP was measured 
continuously with a beat-to-beat BP monitor (Ohmeda 2300, Finapres Medical Systems, 
Amsterdam/NL), BP variability (BPV) was calculated as the standard deviation of BP at each 
CPAP level, the 95% confidence interval (95%CI) was calculated and changes in BP and 
BPV were reported. 
Results 15 patients (12male, 48 ± 10) years, BMI 38.9 ± 5.8 kg/m2) were studied; the 
baseline BP was 131.0 ± 10.2 / 85.1 ± 9.1 mmHg. BP and BPV increased linearly with CPAP 
titration (systolic BP r=0.960, p<0.001; diastolic BP r=0.961, p<0.001; systolic BPV r=0.662, 
p=0.026; diastolic BPV r=0.886, p<0.001). The systolic BP increased by +17% (+23.15 (7.9, 
38.4) mmHg; p=0.011) and the diastolic BP by +23% (+18.27 (2.33, 34.21) mmHg; 
p=0.009), when titrating CPAP to 20cmH2O. Systolic BPV increased by +96% (+5.10 (0.67, 
9.53) mmHg; p<0.001) and was maximal at 14cmH2O, and diastolic BPV by +97% (+3.02 
(0.26, 5.78) mmHg; p<0.001) at 16cmH2O. 
Conclusion Short-term incremental CPAP leads to significant increases in BP and BPV in 
obese patients with OSA while awake. Careful titration of pressures is required to minimise 
the risk of nocturnal awakenings while improving BP control. 
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Introduction 
 
Obstructive sleep apnoea (OSA) is characterised by intermittent episodes of complete or 
partial upper airway obstruction that lead to recurrent apnoeas or hypopnoeas during sleep 
[1]. These respiratory events cause sleep fragmentation and diminished quality of sleep, thus 
leading to excessive daytime sleepiness [2], cognitive dysfunction [3], as well as to increased 
risk of road traffic accidents [4]. OSA is associated with significant comorbidities [5], such as 
cardiovascular disease [6, 7] and hypertension [8], stroke [9], coronary heart disease [10], 
diabetes [11, 12] and the metabolic syndrome [13]. Obesity is an important risk factor for the 
development of OSA and the two conditions share a complex interaction, with poor sleep and 
sleepiness also facilitating weight gain independent of OSA [14, 15]. Obesity [16] and OSA 
[17] are independently related to increased sympathetic tone, hypertension and associated 
comorbidities. 
 
Continuous positive airway pressure (CPAP) is the most effective treatment for OSA [18]. It 
maintains upper airway patency during sleep [19], inflates the chest and offloads the 
respiratory system [20, 21]. When effectively titrated, CPAP reduces OSA symptoms, such as 
sleepiness [22, 23], but also associated breathlessness [24, 25]. Importantly, CPAP improves 
blood pressure (BP) control in sleepy patients with OSA [26] and decreases blood pressure 
variability (BPV) [27]. Thus, it might reduce cardiovascular related mortality and morbidity 
[28].  
 
Indeed, the use of CPAP in OSA was thought to reduce the risk of fatal cardiovascular events 
in both men [29] and women [30], and also in the elderly [31]. However, recent results of the 
SAVE trial have failed to show any long-term cardiovascular benefit in patients with 
underlying cardiovascular disease and OSA, who were established on CPAP [28]. Currently, 
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it remains unclear as to why CPAP has failed to improve long-term cardiovascular risks, but 
patient adherence is likely to contribute to variable long-term outcomes [28, 32].  
 
 
When initiating CPAP therapy pressure titration is crucial for the respiratory control of 
apnoeas and hypopnoeas. Pressure levels impact on patient’s adherence to treatment, in that 
CPAP needs to be tolerable and comfortable [25]. In this context, it is important to recognize 
that short-term CPAP adherence has been shown to predict long-term usage [33] and this 
underlines the importance of utilising acceptable pressure levels for patients early on.  
 
We hypothesised that acute increase in CPAP pressure during titration in obese patients with 
OSA might impact on BP and BPV due to increased intra-thoracic pressures, and that these 
effects need to be taken into account when delivering CPAP in such patients. Hence, we 
sought to systematically assess prospective the beat-to-beat BP while titrating CPAP in the 
awake obese patients with OSA. 
 
 
Methods 
 
Patients were recruited from the Sleep Disorders Centre at Guy’s & St Thomas’ NHS 
Foundation Trust, London, UK. The local Research Ethics Committee approved the study; 
informed written consent was obtained from each participant (06/Q0703/224). Inclusion 
criteria were age older >18 years, a body-mass index (BMI) above >25kg/m2 and confirmed 
OSA, as defined by an apnoea-hypopnea index (AHI) >15/h, AHI >5/h if they were 
symptomatic (Epworth Sleepiness Scale >10 points). Specific exclusion criteria were 
inability to tolerate incremental CPAP titration, or psychological disorders that confounded 
the observation. One patient had an anxiety disorder (claustrophobia) and was excluded from 
 
6 
the study. Another patient requested to stop at 14cmH2O, despite tolerating CPAP titration; 
these data were included in the analysis. All patients had equal and palpable radial arteries, 
they did not have any muscular tension, vascular fistulae, or aortic arch abnormalities that 
might impact upon the accuracy of peripheral blood pressure measurements. Anthropometric 
data were collected including age, gender, height, weight, BMI, neck, waist and hip 
circumference, Mallampati score, and smoking history. 
 
Protocol 
Patient age, gender, height and weight were recorded. An electronic hand-held spirometer 
(Carefusion Micro I, Micromedical, Basingstoke, UK) was used to record the forced 
expiratory volume in one second (FEV1) and the forced vital capacity (FVC) in the seated 
posture with a nose clip. Prior to further measurements patients were asked to rest quietly on 
a bed in a standardised supine posture (legs straight and uncrossed, hands by their side with 
their palms facing down, and head/shoulders supported using a pillow so that they felt no 
efforts to maintain head and neck posture) for five minutes. Patients were studied awake, 
supine at rest (CPAP=0cmH2O) and with a full-face mask (ResMed Mirage Quattro full face 
mask, ResMed Ltd, Oxfordshire, UK), and during incremental CPAP (CPAP S8, Resmed 
Ltd, Oxfordshire, UK) titration (4-20 cmH2O; increments of + 2cmH2O each 3minutes). The 
protocol finished either when patients had reached a CPAP of 20 cmH2O for 3minutes or 
when they felt that the pressures were unpleasant or caused breathlessness. BP was measured 
with a beat-to-beat BP monitor (Ohmeda 2300, Finapres Medical Systems, Amsterdam/NL) 
applied to the middle phalanx of the index finger of each participant, in order to continuously 
measure the finger blood pressure (radial artery of index finger) [34]; this technique has been 
shown to accurately reflect systemic arterial pressure [35]. The device was auto-calibrated at 
the beginning, after 15 minutes and at the end of the CPAP titration, as described elsewhere 
[36]. BPV was calculated as the standard deviation of BP at each CPAP level. Results were 
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analysed with the first minute on a new pressure level disregarded in order to account for 
equilibration of ventilation and increased variability when ramping up the pressures, and the 
last two minutes on each level being analysed and averaged. 
 
Sleep study 
A sleep study was undertaken the night prior to the morning physiological study to determine 
the AHI [37], and the 95th percentile of CPAP that was required to avoid upper airway 
occlusion [38]. The results were analysed and confirmed by expert sleep technicians. 
 
Statistical analysis 
Data were analysed using SPSS V23.0 (SPSS, Chicago, IL/USA). Data were tested for 
normal distribution using the Shapiro-Wilk test. Pearson product-moment correlation 
coefficient was used for bivariate analyses for normally distributed data, Spearman’s rank 
correlation was used for cases with non-normally distributed data. BPV at each CPAP level 
was calculated as the mean of the standard deviation of all patients blood pressure during the 
last 2 minutes on each CPAP pressure. The change in blood pressure from baseline (delta, Δ) 
was calculated for all individuals as the mean BP of the last two minutes at the CPAP level 
which had the highest average reading, minus the mean BP of the last two minutes with no 
CPAP (0cmH2O; mask off). These results were tested using the paired samples t-test. Systolic 
and diastolic blood pressure were expressed as mean ± standard error, the 95% confidence 
interval (95%CI) was reported for BP changes on CPAP. Statistical level of significance was 
defined with a p-value <0.05.  
 
RESULTS 
Patient characteristics 
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15 patients (12males, 48 ± 10 years, BMI 38.9 ± 5.8 kg/m2) with a confirmed diagnosis of 
OSA were studied (Table 1). The patients were middle-aged, predominantly male (80%), and 
obese, with one patient being in the overweight category (number 4). Two patients had mild 
OSA (number 3 and 15) and all others had moderate-severe OSA. Patients had relatively 
normal spirometry. All but one patient completed the study protocol, reaching a CPAP level 
of 20 cmH2O; subject number 2 stopped at 14 cmH2O due to breathing discomfort. A total of 
5 patients had a known history hypertension (number 3, 5, 6, 11, 13), four of whom were 
established on treatment, and one had not been taking treatment. Of the patients not known to 
have hypertension, 4 were hypertensive at baseline based on a diastolic blood pressure > 90 
[39].  
 
BP and BPV 
On CPAP the systolic BP increased by +17% (95%CI: 6-28%; p=0.011) and the diastolic BP 
by +26% (95%CI: 3-49%; p=0.009) (Figure 1). The mean systolic BP variability increased 
maximally from baseline by +96% (95%CI: 13-180%; p<0.001; 0-14 cmH2O), the diastolic 
BPV increased maximally by +97% (95%CI: 8-185%; p<0.001; 0-16 cmH2O; Table 2). 
There were no significant differences between the patients with known hypertension and 
those without (BP, systolic p=0.827; BP, diastolic p=0.274; systolic BPV p=0.868; diastolic 
BPV p=0.556).  
 
CPAP and BP / BPV 
The average change in BP at each incremental CPAP level is displayed in figure 1. The 
average systolic BPV at each CPAP level is displayed in figure 2, and the average diastolic 
BPV at each CPAP level is displayed in figure 3. Incremental CPAP titration was associated 
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with higher systolic (r=0.960, p<0.001) and diastolic BP (r=0.961, p<0.001), as well as with 
higher systolic (r=0.662, p=0.026) and diastolic BPV (r=0.886, p<0.001).  
 
DISCUSSION 
This study showed that the acute application of CPAP in obese patients with OSA while 
awake leads to significant increases in blood pressure and blood pressure variability during 
pressure titration. The diastolic BP rises by up to +23%, and the systolic BP by up to +17%. 
BPV, a marker of sympathetic activity, almost doubles (+96 to 97%) during acute and 
incremental CPAP titration in these patients. There is a strong linear correlation between 
applied level of CPAP and the observed changes.  
 
Clinical Significance of Findings 
Obstructive Sleep apnoea (OSA) is an independent risk factor for cardiovascular morbidity 
and mortality, which is thought to be secondary to increased sympathetic activity, and 
hypertension [40, 41]. This is likely to be mediated by a number of pathways contributing to 
intermittent hypoxia and hypercapnia [42], increased oxidative stress, systemic inflammation 
[43], and amplified sympathetic activity [44]. Patients with OSA exhibit increased 
sympathetic activation while awake and asleep [45]. Amplified sympathetic drive has also 
been described to develop in obese patients, independent of hypertension [46], although the 
degree to which this is related to the underlying OSA is not entirely understood [47]. These 
pathophysiological mechanisms are thought to chronically elevate blood pressure, 
subsequently impacting on endothelial integrity, causing atherosclerosis and hence increased 
cardiovascular morbidity [48]. The impact of intermittent arterial hypoxia on the sympathetic 
nervous system is a central focus of the cardiovascular effects induced by OSA. Chronic 
intermittent periods of hypoxia and hypercapnia result in increased oxidative stress, which in 
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turn lead to chemoreflex stimulation, upregulation of central and peripheral chemoreceptors 
and increased sympathetic nerve activity [49, 50]. Acute changes in sympathetic drive and 
blood pressure have been less well described [45, 51]. 
 
Bonsignore et al [52] found in a similar cohort of 18 obese patients (BMI 35.5 ± 6.1) with 
severe OSA (AHI 58 - 134 events/hr) that CPAP application, by means of preventing apnoeas 
while asleep, decreased systolic and diastolic BPV by improving baroreflex control (no 
difference to absolute BP). They used the Finapres system to record beat-to-beat BP during 
full-night polysomnography; however, their “acute” application of CPAP was overnight with 
a predetermined pressure (average 11.2 ± 3.0 cmH2O) from baseline studies (18 ± 9 days 
earlier) aimed specifically to prevent obstructive events and normalise SaO2 during sleep.  
Likewise, an earlier paper using a Finapres device in a similar cohort of 8 patients (7 male) 
with severe OSA (>4% SaO2 dips/hr: 50.5) who were predominantly obese (BMI 36.9 
km/m2), middle-aged (52 yrs) tried to investigate the cause of post-apnoea blood pressure 
rises. Six of the patients had been studied during the first night of CPAP use, with two 
patients previously being established on CPAP between 2 and 4 years (treatment discontinued 
3 nights earlier). BP was investigated in different stages: firstly, during 30 minutes of 
wakefulness, then during 30 minutes of OSA, followed by 30 minutes of OSA plus 
supplementation of oxygen to maintain saturation >96%, followed by 30 minutes of nasal 
CPAP therapy to avoid apnoeas, hypopnoeas and snoring. Despite the fact that the AHI was 
elevated during the OSA phase compared to CPAP phase, the application of CPAP did not 
reduce systolic or diastolic BP. However, it did cause a reduction in BPV, compared to the 
OSA phase and wakefulness [53].  
Despite similar demographic cohorts and investigational techniques, both of these studies 
have significant methodological differences to our observational investigation of the 
immediate physiological effect of incremental CPAP titration on BP and BPV. Both papers 
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describe the impact on asleep patients, and currently there is limited data demonstrating the 
acute effects of CPAP on BP whilst awake [54]. 
 
Indeed, CPAP as a treatment for OSA is thought to positively impact on cardiovascular 
outcomes [29], as it maintains upper airway patency and avoids recurrent periods of hypoxia, 
arousal and high intra-thoracic pressure changes. However, the results of the recent SAVE 
trial have shown that CPAP may not confer significant benefits with regards to long-term 
cardiovascular outcomes in OSA [28]. By investigating moderate to severe OSA patients 
(n=2,717, mean follow-up 3.7 years) with comorbid cardiovascular disease, the investigators 
reported no benefit in the group that was established on CPAP when compared to usual care 
(hazard ratio 1.10; 95%CI 0.91 to 1.32; p=0.34). The findings were reinforced by an earlier 
study in minimal symptomatic OSA patients [55]. In addition, the SAVE trial may have 
selected less affected OSA patients by excluding those with an Epworth Sleepiness Scale 
>15, and those with severe oxygen desaturations (<80% for >10% of the recording time). 
Furthermore, it did not exclude smokers (15.9% in the CPAP-arm) and compliance in the 
CPAP group was limited to about 3.3-hours (mean operating time per night). Despite this, the 
impact of CPAP on cardiovascular outcomes remains contentious. 
 
These results become important when putting the results of the current study in context: 
CPAP is the most effective treatment to offset upper airway obstruction and, thus, improving 
intermittent hypoxia, arousal and pressure changes that are associated with uncontrolled 
OSA. However, the application of a constant high intrathoracic pressure using CPAP can in 
itself cause relevant increases in systolic and diastolic blood pressure, as well as in BPV, 
which could in itself partially offset the benefits of a good respiratory control. While the 
primary goal of CPAP is to eliminate the OSA syndrome including excessive day time 
sleepiness, the value of avoiding higher CPAP pressures than required to achieve an 
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acceptable respiratory control may need to be discussed further. Assessing neural respiratory 
drive during CPAP titration via diaphragmatic EMG might be one way of achieving this [56]. 
Further, slightly reduced CPAP levels to offset most respiratory events could be enough to 
facilitate long-term respiratory control while reducing problems with compliance [25].  
Previously, the SERVE HF trial had observed an increased risk of cardiovascular death when 
adaptive servo-ventilation (ASV) was utilised to treat central sleep apnoea in patients who 
had heart failure and who were established on maximal medical management. The study 
compared patients with ASV vs patients on maximal medical management only. An increased 
risk of cardiovascular death was observed in patients who had never had a prior hospital 
admission (hazard ratio 2.59, 95% CI 1.54–4.37, p<0.001) and in the group who had 
previously had resuscitation (hazard ratio 1.57, 1.01–2.44, p=0.045) [57]. Long-term 
outcomes were worse in patients with a left ventricular ejection fraction below 45%. 
Although our patient cohort included patients with OSA and not with heart failure the 
immediate impact of acute CPAP on BP in other patient groups should be investigated further 
to understand the impact on cardiovascular pathophysiology. 
 
Limitations 
Our patient cohort (15) is quite small and so the results cannot be widely generalised, though 
the conclusions and hypotheses warrant further and urgent evaluation. Importantly, this was 
an observational study of the acute effects of CPAP. The study does not take into account the 
PAP required to achieve upper airway patency in each patient, and, hence, cannot determine 
the levels of PAP that patients would be exposed to in the long-term.  
 
Beat-by-beat blood pressure was recorded in the sleep laboratory overlooked by a trained 
physician. Hence, a “white coat” effect may have been a confounding factor, although upon 
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completion of CPAP titration patients were observed until their blood pressure had 
normalised again. The studied cohort entailed obese individuals, five patients had a history of 
hypertension and four further patients were slightly hypertensive at baseline measurement. 
Obesity is known to independently increase sympathetic activity [58, 59], as is hypertension 
[60]. These confounders may have exacerbated the observed effect of CPAP on blood 
pressure, and our data should not be generalised to non-obese non-hypertensive patients. 
Obstructive sleep apnoea and hypertension frequently coexist, with hypertension commonly 
discovered in patients with sleep apnoea. Nevertheless, our sub-analysis revealed no 
significant differences between patients with a history of hypertension against those without 
in any of the outcomes. Heart failure is an important comorbidity in this cohort of patients 
and an acute physiological effect of CPAP needs to be considered when pressurising the 
chest.  
 
Recording changes in the blood pressure using a finger-cuff device is considered to be 
reliable [61], however, it is not validated for baseline systolic and diastolic measurements. 
The baseline measurements in this study were recorded using brachial artery blood pressure 
readings in the traditional way. Our finger-cuff device (Finapres) was used only for tracking 
beat-to-beat changes in blood pressure to allow us to calculate both the standard deviation (as 
a measure of blood pressure variability) and the change in blood pressure during CPAP 
titration. Continuous beat-to-beat blood pressure recordings better reflect any haemodynamic 
changes as opposed to intermittent blood pressure readings [62]. 
 
It is noteworthy that the studied patients were awake. CPAP in the sleep laboratory is 
generally used to treat the asleep patient, although it is first applied when still awake. 
However, it is more commonly used in awake patients in other settings, in particular in the 
critically ill patient [63] with acute pulmonary oedema [64]. The short-term impact of acute 
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CPAP on the cardiovascular system might not only alter sympathetic tone but could also 
impact on cardiac function in patients with chronic heart failure, although this is beyond the 
remit of the current investigation. It will be important to establish how BP and BPV respond 
over longer periods that include sleep. In addition, there is a lack of a CPAP control where 
only mask was applied with no added pressure. Although BP in this context would be fairly 
predictable other factors related to a white coat hypertension over time might become 
relevant. 
 
Conclusion 
Acute incremental CPAP leads to an increase in blood pressure and blood pressure variability 
in awake and obese patients with OSA. To systematically address any effects of CPAP on BP 
and BPV it is important to better understand the pathophysiological changes and long-term 
effects of this treatment in OSA patients. Studies in patients with coexisting OSA and heart 
failure are of particular interest. Advanced physiological monitoring of patients with OSA 
while undergoing CPAP titration with a focus on both the intrathoracic and cardiovascular 
components could improve our mechanistic understanding of the value of this treatment. 
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Individual tables and captions 
 
Table 1: Participant demographics and baseline variables, mean and standard deviation (SD). 
FEV1 = forced expiratory volume in one second. FVC = forced vital capacity. SBP = baseline 
systolic blood pressure. DBP = baseline diastolic blood pressure. HTN = hypertension. A = 
Amlodipine, B = Bendroflumethiazide, D = Doxazosin, I/H = Irbesartan/Hydrochlorthiazide, 
R = Ramipril. %pred = precent predicted. 
 
 
 
 
 
 
 
Subject 
(n) 
Age 
(yrs) 
Gender 
BMI 
(kg/m2) 
AHI     
(hrs-1) 
FEV1 
(L/%pred) 
FVC 
(L/%pred) 
FEV1/FVC 
(%) 
 
SBP 
 
DBP HTN Drug 
 
1 34 M 32.6 28.0 3.49 / 81 4.66 / 89 75 132 92 No - 
 
2 38 M 37.2 23.0 4.13 / 102 5.09 / 103 81 131 76 No - 
 
3 54 F 49.7 10.4 1.43 / 70 1.59 / 65 90 132 77 Yes R, A 
 
4 57 M 27.9 51.2 3.64 / 106 4.13 / 96 88 125 98 No - 
 
5 54 M 40.4 77.4 3.09 / 86 3.80 / 84 81 149 98 Yes none 
 
6 54 M 42.6 18.7 3.00 / 83 3.85 / 85 78 127 97 Yes A 
 
7 49 M 36.7 22.6 2.77 / 76 3.53 / 79 79 128 78 No - 
 
8 48 M 38.7 20.0 2.35 / 62 3.79 / 80 62 125 88 No - 
 
9 37 F 37.3 52.0 1.88 / 83 2.68 / 101 70 127 81 No - 
 
10 53 M 30.8 40.0 3.16 / 99 3.60 / 91 88 113 78 No - 
 
11 62 M 41.5 16.3 2.45 / 75 3.62 / 86 68 151 84 Yes B, D 
 
12 46 F 36.4 20.0 1.53 / 63 2.25 / 80 68 134 90 No - 
 
13 60 M 44.7 24.7 3.13 / 93 4.01 / 93 78 144 83 Yes A, I/H 
 
14 31 M 44.9 69.4 4.28 / 90 5.49 / 95 78 131 90 No - 
 
15 37 M 42.1 9.0 3.57 / 92 4.50 / 95 79 132 87 No - 
 
Mean 47.6 3F:12M 38.9 32.2 2.9 / 84.1 3.8 / 83.5 77.5 132 86 n=5  
 
SD 9.9 
 
5.8 21.1 0.9 / 13.3 1.0 / 19.8 8.0 10 8   
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 BP, baseline 
(mean ± sd) 
BP, maximal 
(mean ± sd) 
Δ BP (95%CI) p-value 
BP systolic (mmHg) 137.3 ± 18.9  160.5 ±  23.5  23.2 (7.9, 38.4) 0.011 
BP diastolic (mmHg) 70.0 ± 13.6  88.2 ± 18.5 18.3 (2.3, 34.2) 0.009 
BPV systolic (mmHg) 5.3 ± 2.6 10.4 ±  5.5 5.1 (0.7, 9.5) < 0.001 
BPV diastolic (mmHg) 3.1 ± 1.6  6.2 ± 2.2  3.0 (0.3, 5.8) < 0.001 
 
Table 2: Baseline (0 cmH2O) and maximum blood pressure (BP), blood pressure variability 
(BPV) and change in BP (delta BP: maximum – baseline), analysed using the paired t-test. 
SD = standard deviation. 
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Figure Legends: 
 
Figure 1: CPAP titration and blood pressure changes (mean ± standard error) from baseline 
(n=15). Systolic blood pressure (grey line), diastolic blood pressure (black line). 
 
Figure 2: Systolic blood pressure variability (mean ± standard error) presented at each level 
of CPAP (0-20cmH2O). 
 
Figure 3: Diastolic blood pressure variability (mean ± standard error) presented at each level 
of CPAP (0-20cmH2O). 
 
